{"id":29837,"date":"2016-03-22T09:09:21","date_gmt":"2016-03-22T09:09:21","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=29837"},"modified":"2016-03-22T09:45:25","modified_gmt":"2016-03-22T09:45:25","slug":"msf-call-for-cap-for-mdr-tb-drug-costs-only-180-people-use-delamanid-over-two-years","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/29837","title":{"rendered":"MSF call for cap for MDR-TB drug costs: only 180 people use delamanid over two years"},"content":{"rendered":"<p><strong>MSF press release<\/strong><\/p>\n<p><strong>On 24 February 2016, M\u00e9decins Sans Fronti\u00e8res (MSF) reported in a press release that more than two years after the approval of the new TB drug delamanid, only 180 people globally have used it, due to the high cost.<\/strong> [1]<\/p>\n<p>Delamanid is one of only two new TB drug to be approved in the last 50 years, and is effective against multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB.<\/p>\n<p>Delamanid needs to be taken with other drugs to treat drug-resistant TB. These regimens, without delamanid, cost between $1,000 &#8211; $4,500 per course at the lowest prices available to developing countries. Otsuka, the manufacturer of delamamid, said that it would charge some developing countries US $1,700 per treatment course. [2]<\/p>\n<p>To date, Otsuka has registered delamanid in only four countries (Germany, Japan, South Korea, and the United Kingdom), none of which has a high burden of DR-TB.<\/p>\n<p>MSF demand that the company register delamanid in high DR-TB burden countries and in countries where clinical trials for the drug took place.<\/p>\n<p>To help with widespread scale up of DR-TB treatment, MSF is advocating for a target price of $500 per treatment course for drug-resistant TB.<\/p>\n<p>Dr. Grania Brigden, TB Advisor for MSF&#8217;s Access Campaign said: &#8220;delamanid is neither affordable nor available in most countries today. The price [&#8230;] needs to come down to an affordable level [&#8230;] If people can&#8217;t access delamanid, this promising new drug will be effectively worthless.&#8221;<\/p>\n<p>References:<\/p>\n<ol>\n<li>MSF press release. Developing countries hit with high price for important new tuberculosis drug: More than two years after drug approved, only 180 people globally have received it<br \/>\n<a href=\"http:\/\/www.msfaccess.org\/about-us\/media-room\/press-releases\/developing-countries-hit-high-price-important-new-tuberculosis-dr\">http:\/\/www.msfaccess.org\/about-us\/media-room\/press-releases\/developing-countries-hit-high-price-important-new-tuberculosis-dr<\/a><\/li>\n<li>DR-TB drug regimen prices are from the forthcoming MSF publication, DR-TB Drugs Under the Microscope, 4th Edition, March 2016.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>MSF press release On 24 February 2016, M\u00e9decins Sans Fronti\u00e8res (MSF) reported in a press release that more than two years after the approval of the new TB drug delamanid, only 180 people globally have used it, due to the &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[],"class_list":["post-29837","post","type-post","status-publish","format-standard","hentry","category-treatment-access"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=29837"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29837\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=29837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=29837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=29837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}